Abstract
Background: The CHA2DS2-VASc score has been widely used to predict stroke in patients with atrial fibrillation (AF). Recently, it was reported that the CHA2DS2-VASc score helps predict cardiovascular disease (CVD) or all-cause mortality in patients with or without AF. However, few reports have examined the association between this score and mortality in hemodialysis (HD) patients. Methods: We analyzed 557 consecutive patients who initiated HD at our facilities between February 2005 and October 2017. The CHA2DS2-VASc score was calculated at the time of initiation of HD. Patients were then categorized into three groups according to their CHA2DS2-VASc scores: 0–1 (low), 2–3 (intermediate), and 4–9 (high). Multivariate Cox proportional hazards analysis was used to assess independent risk factors for 3-year all-cause mortality. Results: During the 3-year follow-up period, 153 (27.5%) patients died (cardiovascular death: n = 88). According to multivariate analysis, serum albumin (hazard ratio [HR] 0.60, 95% confidence interval [CI] 0.43–0.85, p = 0.003), creatinine (HR 0.91, 95% CI 0.84–0.99, p = 0.049), and CHA2DS2-VASc score (HR 1.33, 95% CI 1.20–1.46, p < 0.001) were associated with 3-year all-cause mortality. Compared with patients in the low CHA2DS2-VASc score group, those in the intermediate- and high-score groups had a higher risk for all-cause and CVD mortality (all-cause mortality: HR 1.77, 95% CI 1.23–2.55, p = 0.002 and HR 2.94, 95% CI 1.90–4.53, p < 0.001, respectively; CVD mortality: HR 1.82, 95% CI 1.27–2.59, p = 0.001 and HR 2.85, 95% CI 1.88–4.31, p < 0.001, respectively). Conclusion: The CHA2DS2-VASc score is a valuable predictor of 3-year all-cause and CVD mortality in incident HD patients.
References
1.
Cozzolino
M
, Galassi
A
, Pivari
F
, Ciceri
P
, Conte
F
. The cardiovascular burden in end-stage renal disease
. Contrib Nephrol
. 2017
;191
:44
–57
. .2.
Cozzolino
M
, Mangano
M
, Stucchi
A
, Ciceri
P
, Conte
F
, Galassi
A
. Cardiovascular disease in dialysis patients
. Nephrol Dial Transplant
. 2018 Oct 1
;33
(Suppl 3
):iii28
–34
. .3.
Lip
GY
, Nieuwlaat
R
, Pisters
R
, Lane
DA
, Crijns
HJ
. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation
. Chest
. 2010 Feb
;137
(2
):263
–72
. .4.
Glotzer
TV
, Hellkamp
AS
, Lee
KL
, Lamas
GA
. CHA2DS2-VAS(C) and CHADS2 scores predict adverse clinical events in patients with pacemakers and sinus node dysfunction independent of atrial fibrillation
. Can J Cardiol
. 2015 Aug
;31
(8
):1004
–11
.5.
Liu
FD
, Shen
XL
, Zhao
R
, Li
GF
, Wu
YL
, Tao
XX
, Predictive role of CHADS2 and CHA2DS2-VASc scores on stroke and thromboembolism in patients without atrial fibrillation: a meta-analysis
. Ann Med
. 2016 Aug
;48
(5
):367
–75
.6.
Tu
HT
, Campbell
BC
, Meretoja
A
, Churilov
L
, Lees
KR
, Donnan
GA
, Pre-stroke CHADS2 and CHA2DS2-VASc scores are useful in stratifying three-month outcomes in patients with and without atrial fibrillation
. Cerebrovasc Dis
. 2013
;36
(4
):273
–80
.7.
Zimmerman
D
, Sood
MM
, Rigatto
C
, Holden
RM
, Hiremath
S
, Clase
CM
. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis
. Nephrol Dial Transplant
. 2012 Oct
;27
(10
):3816
–22
. .8.
Schamroth Pravda
M
, Cohen Hagai
K
, Topaz
G
, Schamroth Pravda
N
, Makhoul
N
, Shuvy
M
, Assessment of the CHA2DS2-VASc score in predicting mortality and adverse cardiovascular outcomes of patients on hemodialysis
. Am J Nephrol
. 2020
;51
(8
):635
–40
.9.
European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery
; Camm
AJ
, Kirchhof
P
, Lip
GY
, Schotten
U
, Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC)
. Eur Heart J
. 2010 Oct
;31
(19
):2369
–429
.10.
Whelton
PK
, Carey
RM
, Aronow
WS
, Casey
DE
Jr, Collins
KJ
, Dennison Himmelfarb
C
, 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines
. Hypertension
. 2018 Jun
;71
(6
):1269
–324
.11.
American Diabetes Association
. 2 Classification and diagnosis of diabetes: standards of medical care in diabetes-2020
. Diabetes Care
. 2020
;43
(Suppl 1
):S14
–31
.12.
Lu
YA
, Chen
SW
, Lee
CC
, Wu
VC
, Fan
PC
, Kuo
G
, Mid-term survival of patients with chronic kidney disease after extracorporeal membrane oxygenation
. Interact Cardiovasc Thorac Surg
. 2020 Nov 1
;31
(5
):595
–602
.13.
Grundmann
D
, Linder
M
, Goßling
A
, Voigtländer
L
, Ludwig
S
, Waldschmidt
L
, End-stage renal disease, calcification patterns and clinical outcomes after TAVI
. Clin Res Cardiol
. 2021 Nov 13
.14.
März
W
, Genser
B
, Drechsler
C
, Krane
V
, Grammer
TB
, Ritz
E
, German diabetes and dialysis study investigators: atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis
. Clin J Am Soc Nephrol
. 2011 Jun
;6
(6
):1316
–25
.15.
Bae
E
, Cho
HJ
, Shin
N
, Kim
SM
, Yang
SH
, Kim
DK
, Lower serum uric acid level predicts mortality in dialysis patients
. Medicine
. 2016 Jun
;95
(24
):e3701
.16.
Choi
CSR
, Lee
YK
, Cho
AJ
, Park
HC
, Han
CH
, Choi
MJ
, Malnutrition, inflammation, progression of vascular calcification and survival: inter-relationships in hemodialysis patients
. PLoS One
. 2019 May 2
;14
(5
):e0216415
.17.
Anderson
RT
, Cleek
H
, Pajouhi
AS
, Bellolio
MF
, Mayukha
A
, Hart
A
, Prediction of risk of death for patients starting dialysis
. Clin J Am Soc Nephrol
. 2019 Aug 7
;14
(8
):1213
–27
.18.
Kanda
E
, Kato
A
, Masakane
I
, Kanno
Y
. A new nutritional risk index for predicting mortality in hemodialysis patients: nationwide cohort study
. PLoS One
. 2019 Mar 28
;14
(3
):e0214524
. .19.
Robinson
BM
, Zhang
J
, Morgenstern
H
, Bradbury
BD
, Ng
LJ
, McCullough
KP
, Worldwide, mortality risk is high soon after initiation of hemodialysis
. Kidney Int
. 2014 Jan
;85
(1
):158
–65
.20.
Chen
YL
, Cheng
CL
, Huang
JL
, Yang
NI
, Chang
HC
, Chang
KC
, Mortality prediction using CHADS2/CHA2S2DS2-VASc/R2CHADS2 scores in systolic heart failure patients with or without atrial fibrillation
. Medicine
. 2017 Oct
;96
(43
):e8338
.21.
Ntaios
G
, Lip
GY
, Makaritsis
K
, Papavasileiou
V
, Vemmou
A
, Koroboki
E
, CHADS2, CHA2S2DS2-VASc, and long-term stroke outcome in patients without atrial fibrillation
. Neurology
. 2013 Mar 12
;80
(11
):1009
–17
.22.
Onuk
T
, Karataş
MB
, İpek
G
, Güngör
B
, Akyüz
Ş
, Çanga
Y
, Higher CHADS-VASc score is associated with increased mortality in acute pulmonary embolism
. Clin Appl Thromb Hemost
. 2017 Sep
;23
(6
):631
–7
.23.
Hong
C
, Alluri
K
, Shariff
N
, Khattak
F
, Adelstein
E
, Jain
S
, Usefulness of the CHA2DS2-VASc score to predict mortality in defibrillator recipients
. Am J Cardiol
. 2017 Jul 1
;120
(1
):83
–6
.24.
Hsu
PC
, Lee
WH
, Chen
SC
, Tsai
YC
, Chen
YC
, Chu
CY
, Using CHADS2 and CHA2DS2-VASc scores for mortality prediction in patients with chronic kidney disease
. Sci Rep
. 2020 Nov 3
;10
(1
):18942
.25.
Vodošek Hojs
N
, Ekart
R
, Bevc
S
, Piko
N
, Hojs
R
. CHA2DS2-VASc score as a predictor of cardiovascular and all-cause mortality in chronic kidney disease patients
. Am J Nephrol
. 2021
;52
(5
):404
–11
.26.
The United States Renal Data System (USRDS). Available from: https://adr.usrds.org/2020/end-stage-renal-disease/5-mortality.
27.
Kramer
A
, Boenink
R
, Stel
VS
, Santiuste de Pablos
C
, Tomović
F
, Golan
E
, The ERA-EDTA registry annual report 2018: a summary
. Clin Kidney J
. 2020 Dec 24
;14
(1
):107
–23
.28.
Nitta
K
, Goto
S
, Masakane
I
, Hanafusa
N
, Taniguchi
M
, Hasegawa
T
, Annual dialysis data report for 2018, JSDT renal data registry: survey methods, facility data, incidence, prevalence, and mortality
. Ren Replace Ther
. 2020
;6
:41
.29.
Shimoda
T
, Matsuzawa
R
, Yoneki
K
, Harada
M
, Watanabe
T
, Yoshida
A
, Combined contribution of reduced functional mobility, muscle weakness, and low serum albumin in prediction of all-cause mortality in hemodialysis patients: a retrospective cohort study
. J Ren Nutr
. 2018 Sep
;28
(5
):302
–8
.30.
Locham
S
, Mathlouthi
A
, Dakour-Aridi
H
, Nejim
B
, Malas
MB
. Association between severe anemia and outcomes of hemodialysis vascular access
. Ann Vasc Surg
. 2020 Jan
;62
:295
–303
. .31.
Kido
R
, Akizawa
T
, Fukuhara
S
. Haemoglobin concentration and survival of haemodialysis patients before and after experiencing cardiovascular disease: a cohort study from Japanese dialysis outcomes and practice pattern study (J-DOPPS)
. BMJ Open
. 2019 Sep 5
;9
(9
):e031476
. .32.
Stirnadel-Farrant
HA
, Karaboyas
A
, Cizman
B
, Bieber
BA
, Kler
L
, Jones
D
, Cardiovascular event rates among hemodialysis patients across geographical regions-A snapshot from the dialysis outcomes and practice patterns study (DOPPS)
. Kidney Int Rep
. 2019 Mar 28
;4
(6
):864
–72
.33.
Kojima
M
, Inaguma
D
, Koide
S
, Koshi-Ito
E
, Takahashi
K
, Hayashi
H
, Relationship between history of ischemic stroke and all-cause mortality in incident dialysis patients
. Nephron
. 2019
;143
(1
):43
–53
.34.
Findlay
M
, MacIsaac
R
, MacLeod
MJ
, Metcalfe
W
, Sood
MM
, Traynor
JP
, The association of atrial fibrillation and ischemic stroke in patients on hemodialysis: a competing risk analysis
. Can J Kidney Health Dis
. 2019 Sep 27
;6
:2054358119878719
.© 2022 S. Karger AG, Basel
2022
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
